Abstract: The present disclosure relates to 3?3?-cyclic dinucleotides having a carbocyclic nucleotide and derivatives that can modulate the activity of the STING adaptor protein.

Abstract: Provided herein, in some embodiments, are methods for treating age-associated conditions, including systemic inflammation and disease, via enhanced DNA degradation.

Abstract: Embodiments of the present disclosure include methods and compositions for functionalizing molecules, such as oligonucleotides, with functional groups, including polyhistidine tags useful in affinity methods. Some embodiments include methods for modifying and purifying complex mixtures of molecules by exchange of functional tags.

Abstract: The present invention provides an efficient process for the synthesis of (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol and hydrates thereof and methods for treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also provides novel crystalline forms of (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol and hydrates thereof (Form A, Form B, and Form C), characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well as a unique crystalline structure.

Abstract: The present disclosure provides methods of making nicotinoyl riboside compounds or derivatives of formula (I): wherein X?, Z1, Z2, n, R1, R2, R3, R4, R5, R6, R7, and R8 are described herein, reduced analogs thereof, modified derivatives thereof, phosphorylated analogs thereof, and adenylyl dinucleotide conjugates thereof, or salts, solvates, or prodrugs thereof; and novel crystalline forms thereof.

Abstract: The present invention includes Uttroside B compositions and method for the treatment of hepatocellular carcinoma. Chemotherapeutic options for liver cancer are limited and the prognosis of HCC patients remains dismal. Sorafenib, is the only drug currently available for the treatment of hepatocellular carcinoma.

Abstract: The invention relates to nicotinamide mononucleotide, a pharmaceutically acceptable derivative thereof, or a pharmaceutically acceptable salt thereof, for use in preventing and/or treating joint pain induced by physical activity, and compositions comprising same.

Abstract: The present disclosure provides methods and systems for nucleic acid preparation and/or analysis. Nucleic acids may be derived from one or more cells. Nucleic acid preparation may comprise generating nucleic acid molecules of varying lengths. Nucleic acid analysis may comprise identifying nucleic acid sequence information with nucleosome position information.

Abstract: The present disclosure provides prodrugs of 4?-C-substituted-2-halo-2?-deoxyadenoside nucleosides, and compositions, methods, and kits thereof. Such compounds can be useful for treating viral infections including, but not limited to, human immunodeficiency virus.

Abstract: The invention comprises methods for isolating nucleic acids, such as DNA and RNA, while enzyme-inhibiting polyanions are reduced at the same time, using a non-alcoholic binder solution that is not based on chaotropic salts, and a washing solution containing an amine compound, and kits suitable for such a method, comprising the mentioned binder solution and washing solution.

Abstract: The present invention is the use of a small group of purine nucleotide phosphoramidate disclosed herein or a pharmaceutically acceptable salt thereof in an effective amount for the treatment or prevention of the novel 2019 coronavirus disease (COVID-19) in a host, for example a human, in need thereof.

Abstract: A compound useful for treating leukemia or myelodysplastic syndrome, having the structure of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1 is H or —C(?O)—O—R3, and R2 is H or —C(?O)—O—R4, provided R1 and R2 are not both H; and R3 and R4 are each independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, cycloheteroalkyl, and heteroalkyl. In an exemplary compound of formula (I), R1 is —C(?O)—O—CH2—CH3, and R2 is H.

Abstract: The present application relates to a method for preparing trifluridine, comprising reacting a compound of formula III with a compound of formula IV in a first solvent in the presence of an acid to obtain a compound of formula II, and performing further reaction to obtain trifluridine.

Abstract: The disclosure provides cyclic dinucleotides that are useful as STING agonists, pharmaceutical compositions and vaccines comprising the cyclic dinucleotides, and methods of treating diseases and disorders using the cyclic dinucleotides, pharmaceutical compositions, and vaccines.

Abstract: Disclosed are methods of reducing the incidence of necrotizing enterocolitis in an infant, toddler, or child using nutritional compositions including human milk oligosaccharides. The nutritional compositions including the human milk oligosaccharides are effective in reducing inflammation and the incidence of inflammatory diseases.

Abstract: A pharmaceutical composition that includes a compound of the structure: to treat an HCV infected patient with cirrhosis, and uses thereof.

Abstract: The present invention relates to TLR7 agonists according to Formula I and their use in the treatment of diseases such as cancer and infectious disease.

Abstract: A method is provided for preventing and/or treating heart failure in a subject in need thereof by administering to the subject a therapeutically effective amount of polydextrose. The method may also include the use of polydextrose for preventing cardiac remodeling and/or ventricle dilatation and/or for preventing systolic dysfunction, as well as preventing an increase in bacterial translocation to heart tissue in a subject who suffered from a myocardial infarction.

Abstract: The invention discloses a method of isolating nucleic acid and the system thereof, which relates to the following process: (1) providing a biological sample containing cells; (2) performing a cell concentration procedure; (3) performing a magnetic separation procedure through a magnetic separation unit; (4) performing a suspension procedure through a suspending unit; (5) performing a lysis procedure through a lysis unit; and (6) performing a nucleic acid extraction procedure to extract the nucleic acids from the biological samples; wherein the cell concentration procedure does not involve any means of centrifugation. Therefore, the method is simple and efficient, and it is particularly favorable in full automation of nucleic acid isolation. Furthermore, the method and the system as a whole further include a clarification procedure executed by a clarification unit without using centrifugation means, so that improves the quality of nucleic acid isolation.

Abstract: Pharmaceutical compositions comprising a first anti-acne compound, a second anti-acne compound, and an anti-photoaging compound are described. Methods for the treatment of acne and photoaging using the compositions are also described.